FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice.
about
Inhibition of sphingosine kinase-2 in a murine model of lupus nephritisLack of nitric oxide synthases increases lipoprotein immune complex deposition in the aorta and elevates plasma sphingolipid levels in lupusB cells and antibodies in multiple sclerosis pathogenesis and therapy.New approaches for the treatment of lupus nephritis in the 21st century: from the laboratory to the clinic.Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.Sphingosine kinase and sphingosine-1-phosphate: regulators in autoimmune and inflammatory disease.What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy?Modulation of Neuroinflammation in the Central Nervous System: Role of Chemokines and Sphingolipids.Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation.Empowering Regulatory T Cells in Autoimmunity.S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset.Increased serum concentration of sphingosine-1-phosphate in juvenile-onset systemic lupus erythematosus.Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus.Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Sphingosine-1-Phosphate Signaling
P2860
Q34542538-D15672F5-7F68-4567-854B-8475642E322CQ36101077-17E04CF1-0DED-48C4-BC50-7AA634687530Q38050398-F0618CDA-1607-4B45-987E-D92B65E2C514Q38148585-63E8314C-90E4-4BF2-A689-FF2158F59803Q38150110-8FA3DB9C-277C-4CA3-84EE-A6A6DE81D022Q38177794-92EAD8D2-4DA5-4730-B095-5C9568451564Q38590248-218946B8-6E48-433E-AC81-276ED7C02360Q38774697-CA034706-EB51-4C4D-8851-A4999243E2D8Q38869471-E9FB00F6-3A46-413D-B820-9518C50D19A3Q38909420-116A6C2F-9BA6-41CE-9BCE-B89994E35A5DQ47368292-78952AA2-AC19-414C-B057-5AA5AC3284D5Q47683243-5B7DB2AD-29E6-4A47-BE44-B9D17EED88A7Q54935877-746CA117-62D0-448F-A87B-618B0DC90846Q57491423-3580AB9E-8CDC-4631-A2AB-93F5E7D3EB92
P2860
FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
FTY720 exerts a survival advan ...... tion in lupus-prone BXSB mice.
@en
FTY720 exerts a survival advan ...... tion in lupus-prone BXSB mice.
@nl
type
label
FTY720 exerts a survival advan ...... tion in lupus-prone BXSB mice.
@en
FTY720 exerts a survival advan ...... tion in lupus-prone BXSB mice.
@nl
prefLabel
FTY720 exerts a survival advan ...... tion in lupus-prone BXSB mice.
@en
FTY720 exerts a survival advan ...... tion in lupus-prone BXSB mice.
@nl
P2093
P1476
FTY720 exerts a survival advan ...... tion in lupus-prone BXSB mice.
@en
P2093
Hirofumi Amano
Hiromichi Tsurui
Kentaro Minowa
Mareki Ohtsuji
Qingshun Lin
Sachiko Hirose
Seiichiro Ando
Shinji Morimoto
P304
P356
10.1016/J.BBRC.2010.03.078
P407
P577
2010-03-15T00:00:00Z